LifeSci Capital initiated coverage of Prime Medicine (PRME) with an Outperform rating and $6 price target Prime is developing “one-and-done” gene editing therapies centered around indications with significant unmet need, including Wilson’s disease, alpha-1 antitrypsin deficiency, and cystic fibrosis, the analyst tells investors in a research note. The firm is encouraged by the opportunities Prime is targeting in Wilson’s disease and alpha-1 antitrypsin deficiency.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRME:
- Prime Medicine: Buy Rating on Prime Editing Platform Targeting High-Value Liver and Lung Genetic Diseases, Led by PM577 in Wilson’s Disease
- Prime Medicine announces NEJM publication of PM359 data
- Citizens JMP healthcare analysts hold an analyst/industry conference
- Prime Medicine transferred with Neutral rating at JPMorgan
- Cautious Hold Rating for Prime Medicine, Inc. Amid Promising Preclinical Results and Extended Development Timeline